Tennor Therapeutics

Developer of small molecule therapeutics for GI tract infections

placeSuzhou, Jiangsu, China calendar_todayFounded 2013 language tennorx.com

Innovation

29 patent families (2 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 169 times.

YearFilings
20154
20174
20186
20194
20205
20215
20223
20232
20246
20251
20262

Investor mix

13 investors on record; lead investors include AMR Action Fund, Zhongshantoukong.

Investor typeCountShare
Venture capital538%
Private equity215%
Angel & family office18%
Accelerator & incubator18%
Other / undisclosed431%
Coming soon